• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Biotech (General)

Gilead halts emergency access to COVID-19 contender remdesivir amid ‘overwhelming demand’

Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has apparently overwhelmed the Big Biotech. Gilead has temporarily stopped granting patients emergency access to remdesivir under compassionate use due to an “exponential increase” in requests over the last few days,…

UPDATED: Biogen staffer fled to China in search of emergency Covid-19 testing, care — and now faces criminal charges

A Biogen employee who has contracted Covid-19 in Massachusetts fled to Beijing alongside her family. And now she faces criminal charges for lying about her condition on the way back. The company confirmed to Endpoints News that the woman, identified by Chinese officials as Ms. Li, works for the company but said she didn’t attend the strategy…

Alzheimer’s Disease: New Therapeutic Digest eBook

Currently, there are 5.1 million people with Alzheimer’s disease in the United States and 13 million worldwide. In 30 years, AD is expected to affect 13 million in the US, and more than 100 million worldwide. The cost of care for AD in the US is currently estimated at $267 billion and this will balloon…

These are the most disruptive companies shaking up healthcare, executives say

Healthcare executives are keeping their eyes on Amazon. And given the tech giant’s expanding reach in healthcare, that’s not too surprising. But when KLAS Research asked more than 300 healthcare leaders to identify the most potentially disruptive company in healthcare, they found plenty of smaller, emerging companies getting a lot of buzz as well. The company names that…

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Osaka, Japan, and Chicago October 22, 2019 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen specific immune tolerance platform, TAK-101 is…

Biotech GSK gives Clover adjuvant for vaccine against ‘indispensable’ COVID-19 protein

GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells. China’s Clover, which is based 600 miles west of the focal point of…

The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense’s product for ALS patients.

HERZLIYA, Israel, Feb. 6, 2020 /PRNewswire/ — NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients. A Phase IIa study is being conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC), by Prof. Vivian Drory. A similar…

11 drugs likely to become blockbusters

The 11 drugs Clarivate expects to become blockbusters by 2024: Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines. OMG-157 (Novartis) — designed to treat multiple sclerosis. Ozanimod (Celgene) — designed to treat multiple sclerosis. Vadadustat (Akebia Therapeutics/Mitsubishi Tanabe Pharma America/ Otsuka Pharmaceutical) — designed to treat anemia caused by chronic kidney disease. Valrox (BioMarin Pharmaceutical)…

Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases

A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — for the diagnosis and treatment of neurodegenerative diseases, including Parkinson’s disease. Radiochemicals are compounds prepared with radioactive elements that are used for medical applications, such as tracers in positron emission tomography (PET) scans. PET scan…

Major cancer institute sued by its own researchers over ‘tapering’ funding

Alleging that a leading cancer funder is slashing their support in an “unethical and reckless” way, six prominent cancer researchers at the University of California, San Diego (UCSD), have filed a lawsuit to compel it to continue its current level of support. The suit, filed quietly in November 2019 and amended last week, contends that the…